Volume 6.47 | Dec 12

Immune Regulation News 6.47 December 12, 2014
Immune Regulation News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  IRN on Twitter
 
TOP STORY
Injectable 3D Vaccines Could Fight Cancer and Infectious Diseases
Researchers show a non-surgical injection of programmable biomaterial that spontaneously assembles in vivo into a 3D structure could fight and even help prevent cancer and also infectious disease such as HIV. [Press release from the Wyss Institute for Biologically Inspired Engineering discussing online prepublication in Nature Biotechnology] Press Release | Abstract
Learn more about the new smartphone app for human blood cell frequencies
 
PUBLICATIONS (Ranked by impact factor of the journal)
Tissue-Resident Macrophage Enhancer Landscapes Are Shaped by the Local Microenvironment
Scientists profiled the dynamics of four histone modifications across seven tissue-resident macrophage populations. They show that a combination of tissue- and lineage-specific transcription factors form the regulatory networks controlling chromatin specification in tissue-resident macrophages. [Cell]
Abstract | Graphical Abstract

B Cell Super-Enhancers and Regulatory Clusters Recruit AID Tumorigenic Activity
Investigators studied activation-induced cytidine deaminase (AID)-mediated lesions in the context of nuclear architecture and the B cell regulome. They show that AID targets are not randomly distributed across the genome but are predominantly grouped within super-enhancers and regulatory clusters. [Cell]
Abstract | Graphical Abstract

Neutrophils Scan for Activated Platelets to Initiate Inflammation
Investigators report that neutrophil polarization within activated venules served to organize a protruding domain that engaged activated platelets present in the bloodstream. The selectin ligand PSGL-1 transduced signals emanating from these interactions, resulting in the redistribution of receptors that drive neutrophil migration. [Science] Abstract

Interleukin-10-Producing Plasmablasts Exert Regulatory Function in Autoimmune Inflammation
Researchers demonstrate that plasmablasts in the draining lymph nodes serve as interleukin-10 (IL-10) producers to limit autoimmune inflammation and emphasize the importance of plasmablasts as IL-10-producing regulatory B cells. [Immunity] Abstract | Graphical Abstract

Myeloid-Derived Suppressor Activity Is Mediated by Monocytic Lineages Maintained by Continuous Inhibition of Extrinsic and Intrinsic Death Pathways
Using genetic manipulation of cell death pathways, investigators found the monocytic suppressor-cell subset, but not the granulocytic subset, requires continuous c-FLIP expression to prevent caspase-8-dependent, RIPK3-independent cell death. [Immunity] Abstract | Graphical Abstract

Redox and Src Family Kinase Signaling Control Leukocyte Wound Attraction and Neutrophil Reverse Migration
Scientists studied the interactions between macrophages and neutrophils in response to tissue damage in zebrafish and found that macrophages contact neutrophils and induce resolution via neutrophil reverse migration. [J Cell Biol] Abstract | Editorial

Dermal Vγ4+γδ T Cells Possess a Migratory Potency to the Draining Lymph Nodes and Modulate CD8+ T Cell Activity Through Tnf-α Production
A recent study demonstrated that γδ T cells and cutaneous dendritic cells migrate from the skin to the draining lymph nodes (LNs). However, it remains unclear whether they regulate the antigen-specific immune response within the LNs. Researchers investigated their properties and role in the LNs using the Mycobacterium bovis bacille Calmette-Guérin infection model. [J Invest Dermatol] Abstract

Anti-CD33 Chimeric Antigen Receptor Targeting Of Acute Myeloid Leukemia
Researchers generated a second generation CD33-specific chimeric antigen receptor capable of redirecting cytolytic effector T cells against leukemic cells. The CD33-redirected T cells were effective in vivo, preventing leukemia development after prophylactic administration and delaying the progression of established disease in mice. [Haematologica] Abstract | Full Article

Homotypic NK Cell-to-Cell Communication Controls Cytokine Responsiveness of Innate Immune NK Cells
Using a specialized cell-laden microwell approach, scientists discovered that NK cells experiencing constant NK-to-NK contact exhibit a synergistic increase in activation status, cell proliferation, and anti-tumor function in response to IL-2 or IL-15. [Sci Rep] Full Article

Subscribe to our sister publications:
Human Immunology News and Immunology of Infectious Disease News
!

Free Nature Reviews Immunology Poster: The Immune Response to HIV
 
REVIEWS
Potentiation of Immunomodulatory Antibody Therapy with Oncolytic Viruses for Treatment of Cancer
Evidence is emerging that combination therapies using oncolytic viruses and agents targeting immune cosignaling receptors such as 4-1BB, PD-1, and CTLA-4 may work in concert to enhance antitumor immunity and therapeutic efficacy. [Mol Ther Oncolytics] Full Article

Visit our reviews page to see a complete list of reviews in the immune regulation research field.
 
SCIENCE NEWS
Early Trial of New Drug Shows Promise for Patients with Triple-Negative Breast Cancer
In patients with metastatic triple-negative breast cancer—a disease with no approved targeted therapies—infusion of pembrolizumab produced durable responses in almost one out of five patients enrolled in a Phase-Ib clinical trial. [Press release from University of Chicago Medical Center (Newswise, Inc.) discussing research presented at the 2014 San Antonio Breast Cancer Symposium (SABCS), San Antonio] Press Release

Immune Function Marker Does Not Predict Benefit of Trastuzumab in HER-2+ Breast Cancer Patients
A marker of immune function that predicts for better outcomes in patients treated with chemotherapy for triple negative breast cancer—the quantity of tumor-infiltrating lymphocytes (S-TILs) in a biopsy—appears irrelevant when trastuzumab is used. [Press release from Mayo Clinic discussing research presented at the 2014 San Antonio Breast Cancer Symposium (SABCS)] Press Release

MacroGenics Announces Presentation of Pre-Clinical Data on New DART® Candidate MGD011
MacroGenics, Inc. announced the presentation of pre-clinical data for MGD011, a humanized CD19 x CD3 Dual-Affinity Re-Targeting (DART®) protein. [Press release from MacroGenics Inc. discussing research presented at the 56th Annual Meeting of the American Society of Hematology (ASH), San Francisco] Press Release

Immunotherapy Shows Clinical Benefit in Relapsed Transplant Recipients
A multicenter Phase I trial of the immune checkpoint blocker ipilimumab found clinical benefit in nearly half of blood cancer patients who had relapsed following allogeneic stem cell transplantation. [Press release from Dana-Farber Cancer Institute discussing research presented at the 56th Annual Meeting of the American Society of Hematology (ASH), San Francisco] Press Release

From our sponsor: Free mouse hematopoietic progenitors wallchart. Request your copy.
 
INDUSTRY NEWS
Advaxis Announces FDA Acceptance of Its Investigational New Drug Application to Commence Clinical Trials of ADXS-PSA in Combination with Merck’s KEYTRUDA® (Pembrolizumab) for Prostate Cancer
Advaxis, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug application to conduct a Phase I/II clinical study to evaluate the combination of ADXS-PSA with KEYTRUDA® in patients with previously treated, metastatic castration-resistant prostate cancer. [Advaxis, Inc.] Press Release

International Breast Cancer Study Group, Breast International Group and Merck Announce Opening of International PANACEA Study of Patients with HER2+ Breast Cancer
The PANACEA study will investigate the use of pembrolizumab (KEYTRUDA®) in combination with trastuzumab to evaluate whether the addition of an anti-PD-1 therapy can reverse trastuzumab resistance in patients with HER2+ breast cancer whose cancer has spread while on trastuzumab therapy. [Merck & Co., Inc.] Press Release

Immunovaccine Gets FDA Fast Track Status for DPX-Survivac for Ovarian Cancer
Immunovaccine Inc. announced that DPX-Survivac has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) as maintenance therapy in subjects with advanced ovarian, fallopian tube, and peritoneal cancer who have no measureable disease following surgery and front-line platinum/taxane chemotherapy to improve their progression-free survival. [Immunovaccine Inc.] Press Release

FDA Grants Cytori Conditional Approval for a U.S. Pivotal Clinical Trial in Scleroderma
Cytori Therapeutics, Inc. announced that the U.S. Food and Drug Administration has granted conditional approval for an Investigational Device Exemption for a pivotal clinical trial, named the ‘STAR’ trial, to evaluate Cytori Cell Therapy™ as a potential treatment for impaired hand function in scleroderma. [Cytori Therapeutics, Inc.] Press Release
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Keystone Symposium – Neuroinflammation in Diseases of the Central Nervous System
January 25-30, 2015
Taos, United States

NEW 9th World Immune Regulation Meeting
March 18-21, 2015
Davos, Switzerland

NEW The 2nd Gene and Immunotherapy Conference in Vietnam
September 19-20, 2015
Ho Chi Minh City, Vietnam

Visit our events page to see a complete list of events in the immune regulation community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Fellow – Tyrosine Phosphatase in Rheumatoid Arthritis (La Jolla Institute for Allergy & Immunology)

NEW Postdoctoral Position – Immunology (Inserm)

Postdoctoral Research Associate – Immunology (University of Edinburgh)

Postdoctoral Position – Immunology (Centre Léon Bérard)

Postdoctoral Position – Mucosal Immunology (Karolinska Institute)

Research Associate – B Cell Biology (King’s College London)

Researcher – Antitumor Immune Cell Response (ACAVI)

Postdoctoral Fellow – Genetic and Epigenetic Regulatory Networks in Protective Immune Responses (Washington University School of Medicine)

PhD Studentship – Cancer Immunology (Cardiff University)

Scientist – Recombinant Molecules and Antibodies (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Immune Regulation News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Immune Regulation News: Archives | Events | Contact Us